Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada.
Identifieur interne : 000237 ( Main/Exploration ); précédent : 000236; suivant : 000238Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada.
Auteurs : Eve Dubé [Canada] ; Dominique Gagnon ; Marilou Kiely ; Nicole Boulianne ; Monique LandrySource :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- psychologie : Personnel de santé.
- usage thérapeutique : Vaccins antigrippaux, Vaccins atténués.
- Adolescent, Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine, Humains, Mâle, Québec.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Influenza Vaccines, Vaccines, Attenuated.
- geographic : Quebec.
- prevention & control : Influenza, Human.
- psychology : Health Personnel.
- Adolescent, Child, Child, Preschool, Female, Humans, Male.
Abstract
A live attenuated influenza vaccine (LAIV) was offered during the 2012-13 influenza season in Quebec, Canada, to children aged between 2 and 17 years with chronic medical conditions. Despite the offer, uptake of the vaccine was low. We assessed the perceptions and opinions about seasonal influenza vaccination and LAIV use among vaccine providers who participated in the 2012-13 campaign. More than 70% of them thought that LAIV was safe and effective and more than 90% considered that the vaccine was well-received by parents and healthcare professionals. According to respondents, the most frequent concerns of parents about LAIV were linked to vaccine efficacy. LAIV is well-accepted by vaccine providers involved in influenza vaccination clinics, but more information about the vaccine and the recommendations for its use are needed to increase vaccine uptake.
DOI: 10.1080/21645515.2015.1009816
PubMed: 25751608
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada.</title><author><name sortKey="Dube, Eve" sort="Dube, Eve" uniqKey="Dube E" first="Eve" last="Dubé">Eve Dubé</name><affiliation wicri:level="1"><nlm:affiliation>a Québec Institute of Public Health ; Québec , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>a Québec Institute of Public Health ; Québec </wicri:regionArea></affiliation></author><author><name sortKey="Gagnon, Dominique" sort="Gagnon, Dominique" uniqKey="Gagnon D" first="Dominique" last="Gagnon">Dominique Gagnon</name></author><author><name sortKey="Kiely, Marilou" sort="Kiely, Marilou" uniqKey="Kiely M" first="Marilou" last="Kiely">Marilou Kiely</name></author><author><name sortKey="Boulianne, Nicole" sort="Boulianne, Nicole" uniqKey="Boulianne N" first="Nicole" last="Boulianne">Nicole Boulianne</name></author><author><name sortKey="Landry, Monique" sort="Landry, Monique" uniqKey="Landry M" first="Monique" last="Landry">Monique Landry</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25751608</idno><idno type="pmid">25751608</idno><idno type="doi">10.1080/21645515.2015.1009816</idno><idno type="wicri:Area/Main/Corpus">000221</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000221</idno><idno type="wicri:Area/Main/Curation">000221</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000221</idno><idno type="wicri:Area/Main/Exploration">000221</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada.</title><author><name sortKey="Dube, Eve" sort="Dube, Eve" uniqKey="Dube E" first="Eve" last="Dubé">Eve Dubé</name><affiliation wicri:level="1"><nlm:affiliation>a Québec Institute of Public Health ; Québec , Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>a Québec Institute of Public Health ; Québec </wicri:regionArea></affiliation></author><author><name sortKey="Gagnon, Dominique" sort="Gagnon, Dominique" uniqKey="Gagnon D" first="Dominique" last="Gagnon">Dominique Gagnon</name></author><author><name sortKey="Kiely, Marilou" sort="Kiely, Marilou" uniqKey="Kiely M" first="Marilou" last="Kiely">Marilou Kiely</name></author><author><name sortKey="Boulianne, Nicole" sort="Boulianne, Nicole" uniqKey="Boulianne N" first="Nicole" last="Boulianne">Nicole Boulianne</name></author><author><name sortKey="Landry, Monique" sort="Landry, Monique" uniqKey="Landry M" first="Monique" last="Landry">Monique Landry</name></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Health Personnel (psychology)</term><term>Humans</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Quebec</term><term>Vaccines, Attenuated (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Grippe humaine ()</term><term>Humains</term><term>Mâle</term><term>Personnel de santé (psychologie)</term><term>Québec</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>Vaccins atténués (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Quebec</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Personnel de santé</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Health Personnel</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Mâle</term><term>Québec</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A live attenuated influenza vaccine (LAIV) was offered during the 2012-13 influenza season in Quebec, Canada, to children aged between 2 and 17 years with chronic medical conditions. Despite the offer, uptake of the vaccine was low. We assessed the perceptions and opinions about seasonal influenza vaccination and LAIV use among vaccine providers who participated in the 2012-13 campaign. More than 70% of them thought that LAIV was safe and effective and more than 90% considered that the vaccine was well-received by parents and healthcare professionals. According to respondents, the most frequent concerns of parents about LAIV were linked to vaccine efficacy. LAIV is well-accepted by vaccine providers involved in influenza vaccination clinics, but more information about the vaccine and the recommendations for its use are needed to increase vaccine uptake.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25751608</PMID><DateCompleted><Year>2016</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada.</ArticleTitle><Pagination><MedlinePgn>956-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2015.1009816</ELocationID><Abstract><AbstractText>A live attenuated influenza vaccine (LAIV) was offered during the 2012-13 influenza season in Quebec, Canada, to children aged between 2 and 17 years with chronic medical conditions. Despite the offer, uptake of the vaccine was low. We assessed the perceptions and opinions about seasonal influenza vaccination and LAIV use among vaccine providers who participated in the 2012-13 campaign. More than 70% of them thought that LAIV was safe and effective and more than 90% considered that the vaccine was well-received by parents and healthcare professionals. According to respondents, the most frequent concerns of parents about LAIV were linked to vaccine efficacy. LAIV is well-accepted by vaccine providers involved in influenza vaccination clinics, but more information about the vaccine and the recommendations for its use are needed to increase vaccine uptake.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubé</LastName><ForeName>Eve</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>a Québec Institute of Public Health ; Québec , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagnon</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kiely</LastName><ForeName>Marilou</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Boulianne</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Landry</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011792" MajorTopicYN="N" Type="Geographic">Quebec</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CLSC</Keyword><Keyword MajorTopicYN="N">Center local de services communautaires</Keyword><Keyword MajorTopicYN="N">Flumist</Keyword><Keyword MajorTopicYN="N">acceptability</Keyword><Keyword MajorTopicYN="N">attitudes and practices; LAIV</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">intranasal</Keyword><Keyword MajorTopicYN="N">knowledge</Keyword><Keyword MajorTopicYN="N">live attenuated influenza vaccine</Keyword><Keyword MajorTopicYN="N">live attenuated influenza vaccine; TIV</Keyword><Keyword MajorTopicYN="N">local community service center; KAP</Keyword><Keyword MajorTopicYN="N">trivalent inactivated influenza vaccine</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25751608</ArticleId><ArticleId IdType="doi">10.1080/21645515.2015.1009816</ArticleId><ArticleId IdType="pmc">PMC4514394</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Pediatr (Phila). 2003 Sep;42(7):635-40</Citation><ArticleIdList><ArticleId IdType="pubmed">14552523</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Pediatr Adolesc Med. 1995 Aug;149(8):845-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7633536</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Public Health. 1998 Feb;22(1):143-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9599867</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2005 Nov;116(5):e623-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16263976</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2006 Nov;118(5):e1287-92</Citation><ArticleIdList><ArticleId IdType="pubmed">17079529</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2007;5:11</Citation><ArticleIdList><ArticleId IdType="pubmed">17535430</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Nov 7;25(45):7818-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17920170</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Jan 10;26(2):234-40</Citation><ArticleIdList><ArticleId IdType="pubmed">18054818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2008 Oct;122(4):718-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18829793</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Jun 19;27(30):3935-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19467744</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Infect Control. 2009 Sep;37(7):551-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19556035</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2010 Apr;125(4):654-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20194286</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Aug 9;28(35):5731-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20558250</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Oct 18;28(44):7207-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20804802</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pediatr (Phila). 2011 Apr;50(4):338-47</Citation><ArticleIdList><ArticleId IdType="pubmed">21196417</ArticleId></ArticleIdList></Reference><Reference><Citation>Perspect Infirm. 2012 Jan-Feb;9(1):61-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22295461</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Mar 23;30(14):2448-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22300721</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Jun 29;30(31):4632-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22580354</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Jul 6;30(32):4807-12</Citation><ArticleIdList><ArticleId IdType="pubmed">22617633</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Sep 23;31(41):4591-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23896424</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Jan 23;32(5):579-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24315883</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Sep 3;32(39):5071-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25063570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2014;10(8):2483-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25424960</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Boulianne, Nicole" sort="Boulianne, Nicole" uniqKey="Boulianne N" first="Nicole" last="Boulianne">Nicole Boulianne</name><name sortKey="Gagnon, Dominique" sort="Gagnon, Dominique" uniqKey="Gagnon D" first="Dominique" last="Gagnon">Dominique Gagnon</name><name sortKey="Kiely, Marilou" sort="Kiely, Marilou" uniqKey="Kiely M" first="Marilou" last="Kiely">Marilou Kiely</name><name sortKey="Landry, Monique" sort="Landry, Monique" uniqKey="Landry M" first="Monique" last="Landry">Monique Landry</name></noCountry><country name="Canada"><noRegion><name sortKey="Dube, Eve" sort="Dube, Eve" uniqKey="Dube E" first="Eve" last="Dubé">Eve Dubé</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000237 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000237 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25751608
|texte= Acceptability of live attenuated influenza vaccine by vaccine providers in Quebec, Canada.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25751608" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |